NTRK1 and cancer: It has been shown that TrkA small‐molecule inhibitors, such as GTx‐186, HS‐345, CEP‐751, and CEP‐701, decrease the proliferation and growth of pancreatic, ovarian, prostate, thyroid, neuroblastoma, and medulloblastoma cancer cells (Camoratto et al., 1997; Dionne et al., 1998; Evans et al., 1999; Narayanan et al., 2013; Seo et al., 2013).